Penumbra (PEN) Stock Price, News & Analysis

Penumbra, Inc. (NYSE: PEN) is described in its public communications as the world's leading thrombectomy company. The company focuses on developing technologies to address challenging medical conditions that involve blood clots and vascular blockages. Its activities align with the surgical and medical instrument manufacturing industry, and its common stock is listed on the New York Stock Exchange under the symbol PEN, as confirmed in its SEC filings.

According to multiple company press releases, Penumbra concentrates on therapies for ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. The firm highlights a broad portfolio centered on computer assisted vacuum thrombectomy (CAVT™), with an emphasis on removing blood clots "from head-to-toe" with speed, safety and simplicity. These technologies are used by healthcare providers, hospitals and clinics in more than 100 countries, reflecting a global commercial footprint in clot management and vascular care.

In an acquisition announcement with Boston Scientific Corporation, Penumbra is described as having developed a comprehensive portfolio of differentiated devices to treat conditions that include pulmonary embolism, stroke, deep vein thrombosis, acute limb ischemia, heart attack and aneurysms. Within the peripheral vascular space, Penumbra offers mechanical thrombectomy products designed to remove blood clots causing blockages in arterial, venous and pulmonary vessels. Named systems in that announcement include the Lightning Bolt® and Lightning Flash® computer assisted vacuum thrombectomy systems, which are part of its CAVT platform.

Penumbra’s vascular portfolio also includes a minimally invasive peripheral embolization system, described as designed to stop blood flow to control hemorrhaging and bleeding or to close blood vessels. In addition to peripheral vascular tools, Penumbra has neurovascular offerings that encompass access, stroke revascularization and neuro embolization solutions. Company statements indicate ongoing innovation in these areas and efforts to build clinical evidence to support expanded access for more patients worldwide.

Across its disclosures, Penumbra emphasizes that its thrombectomy and embolization technologies are intended for use in complex cardiovascular and vascular diseases where blood clots and impaired blood flow can lead to serious outcomes, such as pulmonary embolism and ischemic stroke. The company positions its CAVT-based systems as advanced mechanical thrombectomy tools that use computer assistance to support clot removal while aiming to maintain safety and procedural efficiency.

Penumbra’s news releases also reference clinical research related to its technologies. The firm has announced results from the STORM-PE randomized controlled trial, a pivotal, multi-center study evaluating computer assisted vacuum thrombectomy using Penumbra’s Lightning Flash™ plus anticoagulation versus anticoagulation alone in patients with acute intermediate-high risk pulmonary embolism. According to the company, STORM-PE demonstrated that CAVT with anticoagulation achieved superior reduction in right heart strain and improvements in thrombus burden, heart rate, oxygen requirement, and functional outcomes compared to anticoagulation alone, with safety rates described as comparable between treatment groups.

In addition to STORM-PE, Penumbra references other prospective data such as STRIKE-PE in its communications, presenting these studies as contributing to the evidence base for CAVT in venous thromboembolism. These clinical programs are cited by the company as part of a multi-year research and development plan and ongoing clinical initiatives to support the use of its thrombectomy technologies in patient care and potential inclusion in treatment guidelines.

From a capital markets perspective, Penumbra regularly reports its financial results and outlook through earnings press releases and associated Form 8-K filings. These communications include information on revenue growth, gross margin, operating margin, and the use of non-GAAP measures such as constant currency revenue, adjusted EBITDA and non-GAAP income from operations. The company explains in detail how these non-GAAP metrics are derived and why its management views them as useful for evaluating the underlying performance of the business.

On January 14, 2026, Penumbra entered into an Agreement and Plan of Merger with Boston Scientific Corporation and a wholly owned Boston Scientific subsidiary, as disclosed in a Form 8-K. Under this agreement, the subsidiary will merge with and into Penumbra, with Penumbra surviving as a wholly owned subsidiary of Boston Scientific. The merger consideration structure includes a mix of cash and Boston Scientific common stock, with stockholder elections subject to proration so that approximately 73% of the aggregate consideration is paid in cash and approximately 27% in stock, as described in the merger filing.

The merger filing further states that, if the merger is consummated, Penumbra’s securities will be delisted from the New York Stock Exchange and deregistered under the Securities Exchange Act of 1934 as promptly as practicable after the effective time. Completion of the transaction is subject to conditions including Penumbra stockholder approval, antitrust and other regulatory clearances, effectiveness of a registration statement for the Boston Scientific shares to be issued, and other customary closing conditions. The merger is not subject to a financing condition.

In the joint acquisition announcement, Boston Scientific notes that the transaction is intended to expand its cardiovascular portfolio and provide a scaled entry into mechanical thrombectomy and neurovascular segments. Penumbra is described in that release as a well-established company with an experienced team and a history of growth and innovation in thrombectomy technologies. The announcement also highlights that Penumbra supports healthcare providers, hospitals and clinics in more than 100 countries, and that its portfolio is aimed at improving patient outcomes and quality of life.

Penumbra also participates in investor conferences and healthcare industry events, as reflected in its press releases about presentations at conferences such as the J.P. Morgan Healthcare Conference, the Piper Sandler Annual Healthcare Conference, and other investor-focused meetings. These events typically feature presentations by Penumbra’s management team, webcasts hosted under the investors section of the company’s website, and discussions of clinical trial data and financial performance.

Overall, based on its own public statements and SEC disclosures, Penumbra, Inc. is a NYSE-listed medical device manufacturer specializing in thrombectomy and embolization technologies for serious vascular and neurovascular conditions, with a portfolio built around computer assisted vacuum thrombectomy and related systems. The company is the subject of a pending acquisition by Boston Scientific that, upon completion, is expected to result in Penumbra becoming a wholly owned subsidiary and its shares being removed from public trading.

Key Business Focus Areas

• Thrombectomy technologies: Mechanical and computer assisted vacuum thrombectomy systems, including Lightning Bolt® and Lightning Flash® CAVT™ systems for peripheral vascular procedures.
• Peripheral vascular care: Devices intended to remove blood clots in arterial, venous and pulmonary vessels, and a peripheral embolization system designed to control bleeding or close blood vessels.
• Neurovascular solutions: Offerings for access, stroke revascularization and neuro embolization, supporting treatment of ischemic stroke and related conditions.
• Clinical evidence: Pivotal trials such as STORM-PE evaluating CAVT plus anticoagulation versus anticoagulation alone in acute intermediate-high risk pulmonary embolism.
• Global reach: Support for healthcare providers, hospitals and clinics in more than 100 countries, as described in company press releases.
• Corporate transaction: Agreement and Plan of Merger with Boston Scientific, under which Penumbra is expected to become a wholly owned subsidiary and its NYSE listing to be discontinued after closing.